Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 4/20 | 0.78 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.78 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.48 |
| ▸ | PARG | Q86W56 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | PLK1 | P53350 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6394445 | 0.91 | MMP13 (0.71) | MMP13SLC22A8GRM4PARGMAPT | |
| SCHEMBL6393638 | 0.91 | MMP13 (0.80) | MMP13SLC22A8GRM4PARGMAPT | |
| SCHEMBL6396382 | 0.90 | MMP13 (0.85) | MMP13SLC22A8GRM4PARGHDAC1 | |
| SCHEMBL6392558 | 0.90 | MMP13 (0.72) | MMP13SLC22A8GRM4PARG | |
| SCHEMBL6395655 | 0.90 | MMP13 (0.81) | MMP13SLC22A8PARGHDAC1TSHR | |
| SCHEMBL6391740 | 0.90 | MMP13 (0.78) | MMP13SLC22A8PARGMAPTHTT | |
| SCHEMBL6390295 | 0.89 | MMP13 (0.63) | MMP13SLC22A8PARGMAPTALDH1A1 | |
| SCHEMBL6390853 | 0.89 | MMP13 (0.62) | MMP13SLC22A8GRM4PARGNPSR1 | |
| SCHEMBL6392191 | 0.88 | MMP13 (0.75) | MMP13SLC22A8GRM4PARGMAPT | |
| SCHEMBL6244295 | 0.88 | MMP13 (1.00) | MMP13SLC22A8PARGALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6962922-B2 | Alkynylated quinazoline compounds | WARNER-LAMBERT COMPANY LLC (US) | 2005-11-08 | — | — | US | claimed |
| US-20050245548-A1 | Alkynylated fused ring pyrimidine compounds | GAUDILLIERE BERNARD | 2005-11-03 | — | — | US | claimed |
| EP-1465878-A1 | ALKYNYLATED FUSED RING PYRIMIDINE COMPOUNDS AS MATRIX METALLOPROTEASE-13 INHIBITORS | Warner-Lambert Company LLC (US) | 2004-10-13 | — | — | EP | claimed |
| WO-2004007469-A1 | NEW ALKYNYLATED QUINAZOLIN COMPOUNDS AS MMP-13 INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-01-22 | — | — | WO | claimed |
| US-20030130278-A1 | Alkynylated fused ring pyrimidine compounds | GAUDILLIERE BERNARD (FR) | 2003-07-10 | — | — | US | claimed |
| WO-2003033478-A1 | ALKYNYLATED FUSED RING PYRIMIDINE COMPOUNDS AS MATRIX METALLOPROTEASE-13 INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2003-04-24 | — | — | WO | claimed |
| US-6962922-B2 | Alkynylated quinazoline compounds | WARNER-LAMBERT COMPANY LLC (US) | 2005-11-08 | — | — | US | disclosed |
| US-20050245548-A1 | Alkynylated fused ring pyrimidine compounds | GAUDILLIERE BERNARD | 2005-11-03 | — | — | US | disclosed |
| EP-1465878-A1 | ALKYNYLATED FUSED RING PYRIMIDINE COMPOUNDS AS MATRIX METALLOPROTEASE-13 INHIBITORS | Warner-Lambert Company LLC (US) | 2004-10-13 | — | — | EP | disclosed |
| WO-2004007469-A1 | NEW ALKYNYLATED QUINAZOLIN COMPOUNDS AS MMP-13 INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-01-22 | — | — | WO | disclosed |
| US-20030130278-A1 | Alkynylated fused ring pyrimidine compounds | GAUDILLIERE BERNARD (FR) | 2003-07-10 | — | — | US | disclosed |
| WO-2003033478-A1 | ALKYNYLATED FUSED RING PYRIMIDINE COMPOUNDS AS MATRIX METALLOPROTEASE-13 INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130278-A1 | Alkynylated fused ring pyrimidine compounds | MMP13, TIMP3, MMP3 | MMP13 1/4885SLC22A8 811/4885GRM4 3817/4885 |
| US-20050245548-A1 | Alkynylated fused ring pyrimidine compounds | MMP13, TIMP3, MMP3 | MMP13 1/4885SLC22A8 827/4885GRM4 3301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.